Page last updated: 2024-09-04
docetaxel anhydrous and ginsenoside rg5
docetaxel anhydrous has been researched along with ginsenoside rg5 in 1 studies
Compound Research Comparison
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (ginsenoside rg5) | Trials (ginsenoside rg5) | Recent Studies (post-2010) (ginsenoside rg5) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 42 | 0 | 42 |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Fan, D; Liu, Y | 1 |
Other Studies
1 other study(ies) available for docetaxel anhydrous and ginsenoside rg5
Article | Year |
---|---|
Ginsenoside Rg5 induces apoptosis and autophagy via the inhibition of the PI3K/Akt pathway against breast cancer in a mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Proteins; Breast Neoplasms; Disease Models, Animal; Docetaxel; Female; Gene Expression Regulation; Ginsenosides; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Panax; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |